Answers are grounded in this paper and cite their sources.
Objective To evaluate the cost-utility of first-line zanidatamab plus chemotherapy, with or without tislelizumab, versus trastuzumab plus chemotherapy for HER2-positive advanced gastroesophageal adenocarcinoma from the Chinese healthcare-system perspective. Methods A partitioned survival model informed by HERIZON-GEA-01 was developed over a 10-year horizon. Costs and health outcomes were discounted at 4.5% annually. Base-case analysis compared costs and quality-adjusted life years (QALYs) across all three strategies and assessed incremental cost-utility. Deterministic and probabilistic sensitivity analyses assessed parameter uncertainty, including survival parameters. Scenario analyses examined alternative survival extrapolations, 5- and 15-year horizons, subsequent-treatment assumptions, adverse-event utility losses, and hypothetical patient assistance programs (PAPs). Price-threshold analyses identified the zanidatamab prices at which each strategy became preferred among all three alternatives. The primary willingness-to-pay threshold was USD 27,917.37/QALY, equivalent to twice China’s per capita GDP in 2025. Results Zanidatamab plus tislelizumab and chemotherapy, zanidatamab plus chemotherapy, and trastuzumab plus chemotherapy generated 2.2414, 1.7196, and 1.4737 QALYs at costs of USD 144,992.86, USD 105,313.53, and USD 29,633.07, respectively. Compared with trastuzumab plus chemotherapy, the corresponding incremental cost-utility ratios were USD 150,270.88/QALY and USD 307,767.29/QALY. Zanidatamab plus chemotherapy was subject to extended dominance. Sensitivity and scenario analyses, including the 5- and 15-year horizons, supported trastuzumab plus chemotherapy as the preferred strategy. Neither zanidatamab-containing regimen achieved positive incremental net monetary benefit in 5,000 probabilistic simulations at the primary threshold. Hypothetical PAPs reduced the pairwise incremental cost-utility ratios to USD 55,749.41/QALY and USD 106,806.31/QALY. Without PAP, simultaneous zanidatamab price reductions of approximately 76.13%–92.87% favored zanidatamab plus chemotherapy, while larger reductions favored the tislelizumab-containing regimen, with ties at boundary prices. Conclusion At the evaluated prices and primary willingness-to-pay threshold, neither zanidatamab-containing regimen was cost-effective in China. Substantial zanidatamab price reductions would be required to change the preferred strategy. Longer follow-up is needed to reassess uncertainty in long-term survival.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: